Application for Breyanzi Accepted for Priority Review by FDA

Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL) - Breyanzi has the potential to be the first and only CAR T cell therapy approved for MZL, addressing a high unmet need - Application based on results from MZL cohort of TRANSCEND FL presented at ICML in which Breyanzi demonstrated high rates of durable responses and a consistent safety profile